← Back to Search

Bright White Light Therapy for Prostate Cancer

Phase 2
Recruiting
Led By William Dale
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 3 months post adt combination treatment initiation
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if bright white light (BWL) therapy can reduce fatigue & depression in prostate cancer patients on ADT therapy, potentially improving quality of life & cancer control.

Who is the study for?
Men over 60 with advanced prostate cancer, eligible for ADT combination therapy, and not currently on other investigational drugs. They should have a life expectancy of at least 18 months, no severe psychological impairments or night shift work, and no recent eye surgery or light sensitivity issues. Participants must be stable with controlled illnesses and without brain metastases or severe sleep disorders.
What is being tested?
The trial is testing if Bright White Light (BWL) Therapy can reduce fatigue and depression in men undergoing ADT combination therapy for advanced prostate cancer. It involves using bright white light to regulate sleep-wake cycles and potentially improve mood by increasing serotonin levels.
What are the potential side effects?
Potential side effects are not explicitly listed but may include discomfort from the brightness of the light, disruption of sleep patterns if improperly timed, mild eye strain, headache or nausea. Severe side effects are unlikely given the non-invasive nature of BWL therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 3 months post adt combination treatment initiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 3 months post adt combination treatment initiation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in patient-reported fatigue
Secondary study objectives
Difference in geriatric assessments
Difference in mood outcomes
Difference in overall quality of life

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group II (Delayed BWL therapy)Experimental Treatment5 Interventions
Patients wear AYOpro BWL therapy glasses starting 6 months after the start of SOC ADT combination therapy for 6 months on trial.
Group II: Group I (Immediate BWL therapy)Experimental Treatment4 Interventions
Patients wear AYOpro BWL therapy glasses starting on day 1 of SOC ADT combination therapy for 12 months on trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bright White Light Therapy
2020
N/A
~80
Combination Drug Therapy
2015
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
602 Previous Clinical Trials
1,923,370 Total Patients Enrolled
8 Trials studying Prostate Cancer
2,151 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,927 Previous Clinical Trials
41,017,795 Total Patients Enrolled
516 Trials studying Prostate Cancer
332,960 Patients Enrolled for Prostate Cancer
William DalePrincipal InvestigatorCity of Hope Medical Center
3 Previous Clinical Trials
473 Total Patients Enrolled

Media Library

Group I (Immediate BWL therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05869682 — Phase 2
Prostate Cancer Research Study Groups: Group I (Immediate BWL therapy), Group II (Delayed BWL therapy)
Prostate Cancer Clinical Trial 2023: Group I (Immediate BWL therapy) Highlights & Side Effects. Trial Name: NCT05869682 — Phase 2
Group I (Immediate BWL therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05869682 — Phase 2
~140 spots leftby Dec 2027